Background Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone. Methods RealFLOT is an Italian, multicentric, observational trial, collecting data from patients with resectable GC or GEJ adenocarcinoma treated with perioperative FLOT. Aim of the study was to describe feasibility and safety of FLOT, pathological complete response rate (pCR), surgical outcomes and overall response rate (ORR) in an unselected real-world population. Additional analyses evaluated the correlation between pCR and survival and the prognostic role of microsatellite instability (MSI) status. Results Of 206 patients enrolled that received perioperative FLOT at 15 Italian centers, 124 (60.2%) received at least 4 full-dose cycles, 190 (92.2%) underwent surgery, and 142 (68.9%) started the postoperative phase. Among patients who started the postoperative phase, 105 (51.0%) received FLOT, while 37 (18%) received de-intensified regimens, depending on clinical condition or previous toxicities. pCR was achieved in 7.3% of cases. Safety profile was consistent with literature. Neutropenia was the most common G 3-4 adverse event (AE): 19.9% in the preoperative phase and 16.9% in the postoperative phase. No toxic death was observed and 30-day postoperative mortality rate was 1.0%. ORR was 45.6% and disease control rate (DCR) was 94.2%. Disease-free survival (DFS) and OS were significantly longer in case of pCR (p = 0.009 and p = 0.023, respectively). A trend towards better DFS was observed among MSI-H patients. Conclusions These real-world data confirm the feasibility of FLOT in an unselected population, representative of the clinical practice. pCR rate was lower than expected, nevertheless we confirm pCR as a predictive parameter of survival. In addition, MSI-H status seems to be a positive prognostic marker also in patients treated with taxane-containing triplets.

Results of the observational prospective RealFLOT study / Giommoni, Elisa; Lavacchi, Daniele; Tirino, Giuseppe; Fornaro, Lorenzo; Iachetta, Francesco; Pozzo, Carmelo; Satolli, Maria Antonietta; Spallanzani, Andrea; Puzzoni, Marco; Stragliotto, Silvia; Sisani, Michele; Formica, Vincenzo; Giovanardi, Filippo; Strippoli, Antonia; Prisciandaro, Michele; Di Donato, Samantha; Pompella, Luca; Pecora, Irene; Romagnani, Alessandra; Fancelli, Sara; Brugia, Marco; Pillozzi, Serena; De Vita, Ferdinando; Antonuzzo, Lorenzo. - In: BMC CANCER. - ISSN 1471-2407. - STAMPA. - 21:(2021), pp. 1086.1-1086.11. [10.1186/s12885-021-08768-7]

Results of the observational prospective RealFLOT study

Giommoni, Elisa;Lavacchi, Daniele;Di Donato, Samantha;Fancelli, Sara;Brugia, Marco;Pillozzi, Serena;Antonuzzo, Lorenzo
2021

Abstract

Background Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone. Methods RealFLOT is an Italian, multicentric, observational trial, collecting data from patients with resectable GC or GEJ adenocarcinoma treated with perioperative FLOT. Aim of the study was to describe feasibility and safety of FLOT, pathological complete response rate (pCR), surgical outcomes and overall response rate (ORR) in an unselected real-world population. Additional analyses evaluated the correlation between pCR and survival and the prognostic role of microsatellite instability (MSI) status. Results Of 206 patients enrolled that received perioperative FLOT at 15 Italian centers, 124 (60.2%) received at least 4 full-dose cycles, 190 (92.2%) underwent surgery, and 142 (68.9%) started the postoperative phase. Among patients who started the postoperative phase, 105 (51.0%) received FLOT, while 37 (18%) received de-intensified regimens, depending on clinical condition or previous toxicities. pCR was achieved in 7.3% of cases. Safety profile was consistent with literature. Neutropenia was the most common G 3-4 adverse event (AE): 19.9% in the preoperative phase and 16.9% in the postoperative phase. No toxic death was observed and 30-day postoperative mortality rate was 1.0%. ORR was 45.6% and disease control rate (DCR) was 94.2%. Disease-free survival (DFS) and OS were significantly longer in case of pCR (p = 0.009 and p = 0.023, respectively). A trend towards better DFS was observed among MSI-H patients. Conclusions These real-world data confirm the feasibility of FLOT in an unselected population, representative of the clinical practice. pCR rate was lower than expected, nevertheless we confirm pCR as a predictive parameter of survival. In addition, MSI-H status seems to be a positive prognostic marker also in patients treated with taxane-containing triplets.
21
1
11
Giommoni, Elisa; Lavacchi, Daniele; Tirino, Giuseppe; Fornaro, Lorenzo; Iachetta, Francesco; Pozzo, Carmelo; Satolli, Maria Antonietta; Spallanzani, Andrea; Puzzoni, Marco; Stragliotto, Silvia; Sisani, Michele; Formica, Vincenzo; Giovanardi, Filippo; Strippoli, Antonia; Prisciandaro, Michele; Di Donato, Samantha; Pompella, Luca; Pecora, Irene; Romagnani, Alessandra; Fancelli, Sara; Brugia, Marco; Pillozzi, Serena; De Vita, Ferdinando; Antonuzzo, Lorenzo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1287009
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact